Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Invested Capital (2023 - 2025)

Protalix BioTherapeutics (PLX) has 3 years of Return on Invested Capital data on record, last reported at 0.1% in Q3 2025.

  • For Q3 2025, Return on Invested Capital rose 53.0% year-over-year to 0.1%; the TTM value through Sep 2025 reached 0.1%, up 53.0%, while the annual FY2024 figure was 0.06%, 1.0% up from the prior year.
  • Return on Invested Capital reached 0.1% in Q3 2025 per PLX's latest filing, down from 0.13% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.13% in Q2 2025 and bottomed at 0.46% in Q2 2024.
  • Average Return on Invested Capital over 3 years is 0.06%, with a median of 0.05% recorded in 2024.
  • Peak YoY movement for Return on Invested Capital: grew 5bps in 2024, then surged 59bps in 2025.
  • A 3-year view of Return on Invested Capital shows it stood at 0.02% in 2023, then skyrocketed by 274bps to 0.07% in 2024, then skyrocketed by 41bps to 0.1% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Invested Capital were 0.1% in Q3 2025, 0.13% in Q2 2025, and 0.08% in Q1 2025.